Toronto Dominion Bank reduced its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 33.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,030,081 shares of the company’s stock after selling 528,744 shares during the period. Toronto Dominion Bank owned approximately 0.05% of Kenvue worth $23,826,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of KVUE. Riverview Trust Co acquired a new stake in Kenvue in the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue in the third quarter valued at about $35,000. Deseret Mutual Benefit Administrators increased its stake in shares of Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after purchasing an additional 651 shares in the last quarter. Studio Investment Management LLC raised its position in shares of Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after purchasing an additional 845 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new position in Kenvue in the 3rd quarter valued at about $71,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have weighed in on the company. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday. Jefferies Financial Group initiated coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $25.00 to $24.00 in a research note on Thursday. Piper Sandler upped their price target on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Finally, Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $22.64.
Kenvue Price Performance
KVUE opened at $22.32 on Friday. The stock’s 50-day moving average price is $22.95 and its 200 day moving average price is $21.17. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a market cap of $42.79 billion, a price-to-earnings ratio of 40.58, a PEG ratio of 2.02 and a beta of 1.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the previous year, the business posted $0.31 earnings per share. The business’s quarterly revenue was down .4% compared to the same quarter last year. As a group, sell-side analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current year.
Kenvue Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.67%. Kenvue’s dividend payout ratio (DPR) is 149.09%.
About Kenvue
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- What is the NASDAQ Stock Exchange?
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- How to Invest in Blue Chip Stocks
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- EV Stocks and How to Profit from Them
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.